Study identifier:D4281C00001
ClinicalTrials.gov identifier:NCT01808092
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults
Nosocomial pneumonia (NP)
Phase 3
No
ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
All
969
Interventional
18 Years - 90 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Feb 2017 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: CAZ-AVI Intra-Venous treatment | Drug: ceftazidim-avibactam (CAZ-AVI, experimental product) 2000mg ceftazidime plus 500mg avibactam |
Active Comparator: Meropenem Intra-Venous treatment | Drug: meropenem (active comparator) 1000mg of Meropenem |